趋化因子CXCL12/CXCR4在非小细胞肺癌中的表达

目的:探讨趋化因子CXCL12及其受体CXCR4在非小细胞肺癌(NSCLC)中的表达及与临床病理特征间的关系。方法:采用免疫组织化学SP三步法检测95例NSCLC患者肿瘤组织及27例肺部良性肿瘤患者(对照组)的石蜡标本中CXCL12、CXCR4的表达情况,并比较其在不同临床病理参数患者间表达的差异。结果:对照组中,CXCL12和CXCR4的高表达率分别为0和7.4%(2/27),NSCLC患者的高表达率分别为54.7%(52/95)和42.1%(40/95),差异均有统计学意义(P<0.01)。在NSCLC中,淋巴结转移组的CXCL12和CXCR4的高表达率(67.2%、51.7%)均高于非转移组(35.1%、27.0%),差异均有统计学意义(P<0.05)。CXCL12、CXCR4的高表达率均随TNM分期的增高而逐渐增高,且Ⅲ期的高表达率明显高于Ⅰ期,差异有统计学意义(P<0.01)。NSCLC患者CXCL12与CXCR4之间无明显相关性。不同年龄、性别、肿瘤大小、组织学分型及分化程度NSCLC患者之间CXCL12、CXCR4的高表达率差异无统计学意义(P>0.05)。结论:CXCL12、CXCR4的表达水平可作为判断NSCLC预后的参考指标。

Expression of Chemokine CXCL12/CXCR4 in Non-Small Cell Lung Cancer

Objective: To investigate the relationship between the protein expression of chemokine CXCL12 and its receptor CXCR4 in tissues of non-small cell lung cancer (NSCLC), and the clinical pathological features thereof. Methods: Expressions of CXCL12 and CXCR4 in NSCLC tissues (n=95) and benign tumor tissues (n=27) were detected by immunohistochemical staining. The relationship between CXCL12/CXCR4 protein expression and clinical pathologic features was analyzed. Results: The high expression rates of CXCL12 and CXCR4 were 0 and 7.4% (2/27) in control group,and 54.7% (52/95) and 42.1% (40/95) in NSCLC group. The difference between expression of CXCL12 and CXCR4 was significant between two groups (P < 0.01). In NSCLC group, the expression rates of CXCL12 and CXCR4 were higher in patients with lymph node metastasis(67.2% and 51.7%) than those of patients without lymph node metastasis(35.1% and 27.0%) (P < 0.01). The higher expressions of CXCL12 and CXCR4 were closely associated with TNM stage. The high expression rate was significantly higher in stage Ⅲ than that in stage Ⅰ (P < 0.05). There was no significant correlation between expressions of CXCL12 and CXCR4 in NSCLC patients. There were no significant differences in high expressions of CXCL12 and CXCR4 between age, gender, tumor size, histological type and degree of differentiation of tumor (P > 0.05). Conclusion: The expression levels of CXCL12 and CXCR4 can be used to evaluate the potential prognosis in patients with NSCLC.